C HEALTH GP has launched multiple AI-RWS studies, leading the new track of "AI + Clinical Research."

According to the announcement from China Healthcare Group (08225), the "AI-RWS Real World Research Summit Forum" was successfully held in Shanghai recently, launching more than ten AI-driven real-world research (AI-RWS) projects targeting two major prevalent mental and neurological disorders: mental disorders in Chinese adolescents and behavioral and psychological symptoms of dementia (BPSD). This marks a key step in the company's strategic layout in the "AI + Clinical Research" track in the Hong Kong stock market, further consolidating its leading position in the industry.

1. Academic and Research System

The forum brought together 40 authoritative experts in pediatric, adolescent psychiatry, and geriatric cognitive impairment from China, learning from Stanford University and Mayo Clinic, and referencing the latest evidence-based guidelines from JAMA Psychiatry 2024 to construct a full-cycle closed-loop research system of "AI intelligent classification - personalized treatment path optimization - dynamic prediction of efficacy and safety - early warning of relapse risk." This system integrates technologies such as NLP and deep learning, consolidating multi-dimensional real-world data to provide high-level real-world evidence (RWE) that aligns with the characteristics of the Chinese population for the two major diseases.

2. Core Track Layout and Key Products

1. Hundred Billion Youth Mental Disorder Track: Targeting over 30 million patients in China, an AI-RWS cohort study covering more than 30 institutions in 15 cities nationwide and over 10,000 patients has been launched. Simultaneously, the Happy Heart adolescent real-world study is being conducted—exploring the co-morbidity of Happy Heart six combined or sequential treatments, involving new drug groups such as Happy Heart A, Happy Heart E, Happy Heart L, Happy Heart A, Happy Heart S, and Happy Heart L. Through self-developed AI algorithms, three major innovative services will be realized: first, optimizing research plans for children's mental health; second, conducting co-morbidity studies for new drug groups; third, predicting the future course of the disease; relevant results will support the iteration of clinical diagnosis and treatment norms and the formulation of medical insurance policies.

2. Trillion Yuan Dementia and BPSD Track: The "Star Plan" has been launched to build the largest and longest-followed BPSD real-world database in China, planning to include 100,000 patients within five years, focusing on research such as non-drug interventions and combination therapies, providing key data for innovative drug registration and post-marketing safety reevaluation.

• The core of clinical research in this track: the company has obtained exclusive clinical research experimental rights and real-world clinical research exclusive rights for Xi'enka micro-tablets and Xi'enmei flash tablets in China.

• The core product of clinical research in this track, Xi'enka micro-tablets, enjoys exclusive formulation globally and is covered by national medical insurance. It is a Grade A recommended product for treating mild to moderate dementia with Level 1 evidence; it uses VSMART patented technology, which can solve swallowing difficulties, mix with liquid food, avoid gastrointestinal reactions, and has superior treatment effects for patients with mental and Parkinson's disorders compared to other similar products.

3. Commercialization Path and Future Outlook

The company adopts a diversified funding model of "co-construction with research hospitals + pharmaceutical company entrustment + government special projects + insurance co-payment," with individual projects expected to be valued from tens of millions to billions. Relying on platforms such as Boao in Hainan and Hengqin, the time for partners' Phase IV clinical research can be shortened by more than 30%, and research results will be synchronized with the advantages of core products to align with the relevant strategies of the National Health Commission, possessing policy dividend advantages In the future, the company will focus on AI-RWS research and the development of intelligent agents for doctors, with a core layout in three major areas: the Xixin mental health brand, the Xien neurological brand, and the Baimin allergy brand, aiming to become a global leader in this field; accelerating the transformation towards AI-driven clinical research services to create superior value returns for shareholders